BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 32209185)

  • 1. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
    Zhao H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary pulmonary lymphoepithelioma-like carcinoma.
    Fan Y; Li C; Qin J; Lu H
    Med Oncol; 2020 Mar; 37(3):20. PubMed ID: 32146584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
    Wu Q; Wang W; Zhou P; Fu Y; Zhang Y; Shao YW; Jiang L
    Pathol Res Pract; 2020 Aug; 216(8):153043. PubMed ID: 32703503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Lymphoepithelioma-like Carcinoma.
    Sathirareuangchai S; Hirata K
    Arch Pathol Lab Med; 2019 Aug; 143(8):1027-1030. PubMed ID: 30672338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
    Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.
    Tang L; Chen N; He W; Zhou J; Zhang J; Lin Z; Wang Z; Hao J; Lin F
    PLoS One; 2020; 15(10):e0240729. PubMed ID: 33064745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma.
    Fan Y; Shan Q; Gong J; Qin J; Lu H
    Front Mol Biosci; 2021; 8():736940. PubMed ID: 34760925
    [No Abstract]   [Full Text] [Related]  

  • 9. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
    Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
    Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up.
    Liang Y; Wang L; Zhu Y; Lin Y; Liu H; Rao H; Xu G; Rong T
    Cancer; 2012 Oct; 118(19):4748-58. PubMed ID: 22359203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival.
    Fang W; Hong S; Chen N; He X; Zhan J; Qin T; Zhou T; Hu Z; Ma Y; Zhao Y; Tian Y; Yang Y; Xue C; Tang Y; Huang Y; Zhao H; Zhang L
    Oncotarget; 2015 Oct; 6(32):33019-32. PubMed ID: 26361045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
    Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological characteristics and cancer-specific prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a population study of the US SEER database and a Chinese hospital.
    Zhang Q; Dai Y; Jin L; Shi S; Liu C; Rong R; Sun W; Dai S; Kong H; Xie W
    Front Oncol; 2023; 13():1103169. PubMed ID: 37274245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
    Dalvi T; Nørgaard M; Fryzek JP; Movva N; Pedersen L; Pham Hansen H; Walker J; Midha A; Shire N; Boothman AM; Rigas J; Mellemgaard A; Rasmussen TR; Hamilton-Dutoit S; Cronin-Fenton D
    PLoS One; 2023; 18(4):e0284037. PubMed ID: 37040387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
    Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
    BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary pulmonary lymphoepithelioma-like carcinoma in Singapore.
    Tay CK; Chua YC; Takano A; Min Chee MY; Lim WT; Lim C; Koh MS
    Ann Thorac Med; 2018; 13(1):30-35. PubMed ID: 29387253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.